Exothera partners with Quantoom and launches the DNA business unit

Exothera has partnered with Quantoom Biosciences to gain access to Quantoom’s Nfinity technology, a sustainable production platform for RNA.

This partnership will allow Exothera to become the first CDMO in the world to offer this turnkey process for the continuous production of RNA as a service. Continuous manufacturing of RNA can provide significant gains in terms of efficiency, productivity, quality control, cost-effectiveness and scalability.

Exothera will provide these services through a new business unit, Exothera Nucleic Acids, which is focused on accelerating process development and manufacturing of vaccines and RNA therapy.

Exothera said the partnership will enable biotechnology and pharmaceutical companies to simplify the development of RNA vaccines and accelerate their clinical and commercial timelines. Leveraging Nfinity’s technology, Exothera will offer development services, non-GMP and GMP manufacturing as well as analytical services to pharmaceuticals/biotechnology for the development of mRNA and saRNA therapies.

Exothera wants to develop the RNA vaccine market

Thibault Jonckheere, CEO of Exothera, said: “The market potential for RNA therapy continues to grow and expand into new therapeutic areas, but the process of developing new vaccines or RNA therapies is hindered by obsolete technologies that were never intended for scale commercialization. . We are excited not only to announce the launch of our new business unit focused on nucleic acids, but also our strategic collaboration with Quantoom Biosciences.”

“This collaboration enables Exothera to manufacture the highest quality RNA for vaccines and therapeutics with low-risk process development and nearly guaranteed product quality from sequence to mass production in far less time than before.”

“We are very excited about this new partnership which marks a new milestone for Quantoom, added José Castillo, CEO of Quantoom.

“The advantages of sustainably manufacturing RNA are clear, and we believe this partnership will provide significant benefits to biotech and pharmaceutical companies developing RNA vaccines and therapeutics. By combining Exothera’s expertise with our state-of-the-art platform, we are able to simplify processes and accelerate timelines for RNA development and production. We are excited to see the impact this partnership has on the industry and ultimately, on patients’ lives.”

Source link

Related Articles

Back to top button